Inflammatory activation within the central nervous system involving Microglia, astrocytes, and infiltration of peripheral immune cells, triggered by DAMPs, PAMPs, metabolic stress, or chronic stress. Can be acute and protective (pathogen clearance, debris removal) or chronic and neurodegenerative (sustained cytokine production, synaptic pruning, neuronal damage). Represents a failure of immune resolution in the brain.
Think of your brain as a sterile research laboratory with a specialized cleanup crew (Microglia) and support staff (astrocytes) who maintain perfect conditions for delicate experiments (neuronal signaling). The lab has tight security doors (blood-brain barrier) that keep street-level chaos out.
When acute neuroinflammation happens—say, a viral infection or head injury—it's like a controlled alarm. The cleanup crew switches from gentle dusting to emergency mode: they release chemical signals (IL-1β, TNF-α, Interleukin-6), recruit more workers, and clear the threat. The alarm shuts off when the danger passes, support staff repair damage, and the lab returns to normal.
But chronic neuroinflammation is like the alarm never turning off. The cleanup crew stays in combat mode indefinitely, pumping out inflammatory chemicals 24/7. The security doors start leaking (blood-brain barrier disruption), letting in street-level immune cells that don't belong in a sterile lab. The constant chemical fog damages the delicate experimental equipment (neurons lose synapses, BDNF production drops, glutamate accumulates to toxic levels). Areas with thinner security walls—like the Arcuate nucleus in the Hypothalamus—get contaminated first, disrupting hunger signals (Leptin resistance) and metabolic control. Eventually, the lab can't function: experiments fail (cognitive decline), equipment breaks down (neurodegeneration), and the whole facility becomes hostile to the precision work it was designed for.
Neuroinflammation is initiated when Microglia—the brain's resident immune cells—detect danger signals:
Triggering Pathways:
Microglial Activation Cascade:
graph TD
A[Danger Signal - LPS/DAMPs/Stress] --> B[Microglial TLR4/NLRP3/RAGE]
B --> C["NF-κB activation"]
C --> D[Gene transcription]
D --> E["IL-1β, TNF-α, IL-6, ROS"]
E --> F1[Neuron damage]
E --> F2[Astrocyte activation]
E --> F3[BBB disruption]
F3 --> G[Peripheral immune cell infiltration]
G --> H[Amplification loop]
H --> E
F1 --> I[Reduced BDNF]
F1 --> J[Glutamate excitotoxicity]
F1 --> K[Oxidative stress]
I --> L[Impaired neuroplasticity]
J --> L
K --> L
L --> M[Cognitive decline/Depression]
Molecular Details:
-
Microglial phenotype shift: Surveillance M0 → activated M1 (proinflammatory)
-
Cytokine cascade:
-
BBB breakdown:
-
Neurotoxic mechanisms:
-
Chronic amplification:
- astrocytes activated by microglial cytokines → reactive astrogliosis → produce more IL-6, TNF-α
- Loss of astrocytes glutamate buffering, K⁺ homeostasis, metabolic support
- Damaged neurons release more DAMPs → perpetuates microglial activation
- cortisol resistance prevents resolution (normally cortisol→suppress NF-kB→terminate inflammation)
Resolution failure: Chronic neuroinflammation represents deficiency in specialized pro-resolving mediators (SPMs) (Resolvins, Protectins, Maresins) in brain tissue, impaired efferocytosis (clearance of dead cells), and persistent NF-kB activation.
Primary Clinical Relevance:
Neuroinflammation is the mechanistic bridge between systemic stressors and brain-based pathology in cPNI. It explains why gut dysbiosis, chronic stress, metabolic syndrome, and ACEs converge on mental health outcomes.
Key Patient Populations:
-
Neurodegenerative diseases:
-
Psychiatric conditions:
-
Metabolic-brain axis:
-
Chronic pain syndromes:
Metamodel Connections:
- Selfish systems: selfish brain theory — neuroinflammation reflects brain prioritizing immediate threat response over long-term neuroplasticity
- Evolutionary mismatch: Chronic activation of acute defense (designed for infections/injury) by modern stressors (chronic stress, Western diet, sedentary behavior)
- 5+2 Metamodel: Neuroinflammation impacts all pillars—movement (reduces motivation via fatigue), nutrition (drives cravings via hypothalamic dysfunction), stress (impairs HPA axis regulation), sleep (disrupts circadian via cytokines), cold/heat (impaired thermoregulation)
Intervention Targets:
-
Upstream prevention:
-
Direct anti-inflammatory:
-
Biomarker monitoring:
- Peripheral: CRP >3 mg/L, IL-6 >10 pg/mL suggest systemic inflammation affecting brain
- Direct: Imaging with PET tracers (TSPO for activated microglia—research setting)
- Functional: cognitive decline, mood disorders, fatigue triad as clinical signature
Exam-Relevant Point: Neuroinflammation in Nucleus Arcuatus explains why systemic inflammation (from obesity, gut dysfunction) directly impairs metabolic hormone signaling (Leptin, Insulin, Ghrelin), creating vicious cycle of weight gain and inflammation.
- Chronic neuroinflammation characterized by sustained IL-1β, TNF-α, Interleukin-6 production for weeks-to-years (vs. hours-to-days in acute)
- Microglia comprise 10-15% of brain cells; activated microglia consume 3-fold more glucose than resting state, competing with neurons
- Nucleus Arcuatus and other Circumventricular organs lack traditional blood-brain barrier → first brain regions affected by peripheral inflammation
- LPS from dysbiosis can reach brain via Vagus nerve signaling, Circumventricular organs sensing, or direct BBB crossing if barrier compromised
- IL-6 levels >10 pg/mL in blood correlate with treatment-resistant Depression
- Neuroinflammation reduces BDNF by 30-50% in Hippocampus, impairing neurogenesis and Long-Term Potentiation (LTP)
- glutamate levels rise 2-3 fold in neuroinflammation → excitotoxicity via NMDA receptor overstimulation
- ACEs predict elevated CRP and IL-6 in adulthood → suggests neuroinflammation as mechanism for ACE→mental health outcomes
- M1 (proinflammatory) microglia express iNOS, produce Nitric Oxide; M2 (anti-inflammatory) express arginase, produce ornithine for tissue repair
- Specialized pro-resolving mediators (SPMs) (resolvins, protectins) levels are reduced 40-60% in Alzheimer's brain tissue vs. controls
- cortisol resistance in Microglia develops with chronic stress → loss of cortisol's normal anti-inflammatory brake → perpetual activation
- Neuroinflammation impairs insulin signaling in brain → contributes to "type 3 diabetes" hypothesis of Alzheimer's Disease
- Exercise reduces microglial activation markers within 12 weeks (measured by TSPO-PET imaging in humans)
- Hypothalamic inflammation occurs within 3 days of high-fat diet in rodents, before significant weight gain
- Microglia — Primary mediators of neuroinflammation; shift from surveillant M0 to proinflammatory M1 phenotype releasing cytokines
- blood-brain barrier — BBB disruption via TNF-α and IL-1β allows peripheral leukocyte infiltration amplifying neuroinflammation
- Arcuate nucleus — Thin BBB makes arcuate vulnerable to neuroinflammation causing leptin and insulin resistance
- BDNF — Neuroinflammation suppresses BDNF via IL-1β/NF-κB interference, impairing neuroplasticity and synaptogenesis
- Depression — Neuroinflammation drives depression via IDO activation, serotonin depletion, impaired reward circuitry
- LPS — Gut-derived LPS triggers neuroinflammation via TLR4 in circumventricular organs or vagal signaling
- IL-1β — Master proinflammatory cytokine requiring NLRP3 inflammasome activation; drives glutamate excitotoxicity
- TNF-α — Disrupts BBB tight junctions, activates neuronal death pathways, inhibits BDNF
- Interleukin-6 — Dual role: acute neuroprotection vs chronic neurotoxicity via trans-signaling
- NF-kB — Central transcription factor in neuroinflammation; normally suppressed by cortisol but resistant in chronic stress
- dysbiosis — Gut dysbiosis increases LPS translocation, peripheral inflammation signals to brain
- chronic stress — Sustained cortisol/catecholamines induce glucocorticoid resistance in microglia perpetuating neuroinflammation
- Oxidative Stress — Neuroinflammation generates ROS via iNOS and NADPH oxidase damaging neurons
- glutamate — Inflammatory cytokines increase glutamate release and impair astrocyte clearance causing excitotoxicity
- Leptin — Hypothalamic neuroinflammation induces leptin resistance disrupting satiety signaling
- Insulin — Brain insulin resistance develops from hypothalamic inflammation impairing glucose metabolism and cognition
- Ghrelin — Hypothalamic inflammation disrupts ghrelin signaling contributing to appetite dysregulation
- Hypothalamus — Particularly vulnerable to neuroinflammation affecting metabolic and stress hormone regulation
- astrocytes — Activated by microglial cytokines to reactive phenotype; lose glutamate buffering and metabolic support functions
- Vagus nerve — Transmits peripheral inflammation signals to brainstem initiating neuroinflammation
- Circumventricular organs — Lack tight BBB allowing peripheral cytokines and LPS direct brain access
- IDO — Upregulated by inflammation shunting tryptophan to neurotoxic quinolinic acid vs serotonin
- KYNA — Kynurenic acid is neuroprotective branch of kynurenine pathway reduced in neuroinflammation
- quinolinic acid — Neurotoxic NMDA agonist elevated in neuroinflammation driving excitotoxicity
- Hippocampus — Neuroinflammation impairs hippocampal neurogenesis and LTP causing memory deficits
- amygdala — Neuroinflammation in amygdala heightens threat reactivity contributing to anxiety
- Alzheimer's Disease — Chronic microglial activation around plaques drives synapse loss and neurodegeneration
- cognitive decline — Neuroinflammation disrupts synaptic plasticity, neurogenesis, neurotransmitter balance
- Anxiety — Neuroinflammation in amygdala and hippocampus impairs fear extinction and emotional regulation
- ACEs — Adverse childhood experiences induce lasting neuroinflammation via epigenetic changes and HPA axis dysregulation
- CRP — Peripheral CRP >3 mg/L indicates systemic inflammation likely affecting brain
- Omega-3 fatty acids — EPA and DHA are substrates for SPM synthesis promoting resolution of neuroinflammation
- Exercise — Reduces microglial activation, upregulates BDNF, promotes M2 anti-inflammatory phenotype
- specialized pro-resolving mediators (SPMs) — Resolvins, protectins, maresins are deficient in neuroinflammation; promote efferocytosis and resolution
- neuroplasticity — Impaired by neuroinflammation through BDNF suppression and synaptic pruning
- Type 2 Diabetes — Metabolic dysfunction drives hypothalamic neuroinflammation creating brain insulin resistance
- obesity — Adipose-derived inflammation and leptin resistance linked to hypothalamic neuroinflammation
- Module 4 — Neuroinflammation in context of brain-immune interface and psychiatric pathology
- Module 8 — Neuroinflammation as mechanism linking metabolic dysfunction to brain pathology